792 related articles for article (PubMed ID: 9684690)
21. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
[TBL] [Abstract][Full Text] [Related]
22. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
23. Renal osteodystrophy.
Coburn JW; Henry DA
Adv Intern Med; 1984; 30():387-424. PubMed ID: 6397042
[TBL] [Abstract][Full Text] [Related]
24. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
[TBL] [Abstract][Full Text] [Related]
25. Adynamic bone disease in patients with uremia.
Fournier A; Yverneau PH; Hué P; Said S; Hamdini N; Eldin HM; Mohageb S; Oprisiu R; Marie A; Solal ME
Curr Opin Nephrol Hypertens; 1994 Jul; 3(4):396-410. PubMed ID: 8076143
[TBL] [Abstract][Full Text] [Related]
26. Low calcium dialysate and hyperparathyroidism.
Duncan R; Cochrane T; Bhalla C; Michael J; Richards NT; Adu D
Perit Dial Int; 1996; 16 Suppl 1():S499-502. PubMed ID: 8728256
[TBL] [Abstract][Full Text] [Related]
27. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
28. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
29. Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients.
Hardy P; Morinière PH; Tribout B; Hamdini N; Marié A; Bouffandeau B; Pruna A; Fournier A
J Nephrol; 1999; 12(6):398-403. PubMed ID: 10626831
[TBL] [Abstract][Full Text] [Related]
30. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
31. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
[TBL] [Abstract][Full Text] [Related]
32. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
33. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
34. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
[TBL] [Abstract][Full Text] [Related]
35. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
Piraino B; Chen T; Puschett JB
Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
[TBL] [Abstract][Full Text] [Related]
36. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
[TBL] [Abstract][Full Text] [Related]
37. Fluoride and dialysis osteodystrophy: results of a double-blind study.
Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
[No Abstract] [Full Text] [Related]
38. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
Sechet A; Hardy P; Hottelart C; Rasombololona M; Abighanem O; Oualim Z; Brazier M; Achard JM; Pruna A; Moriniere P; Fournier A
Artif Organs; 1998 Jul; 22(7):564-8. PubMed ID: 9684692
[TBL] [Abstract][Full Text] [Related]
39. Calcium metabolism in renal failure.
David DS
Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
[TBL] [Abstract][Full Text] [Related]
40. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
